Retatrutide 10mg
Premium pen for easy and precise application. Triple agonist of GLP-1, GIP and glucagon.
Choose a variant
This product is intended exclusively for laboratory and research purposes. Not intended for direct use or human consumption. For persons over 18 years of age only.
About the product
Retatrutide is a triple agonist of the GLP-1, GIP and glucagon receptors, delivered as a premium injection pen. Designed for research into metabolism and body-weight regulation.
Phase II clinical trials demonstrated exceptional results in metabolic regulation. The product is available as a pre-filled injection pen for precise and convenient application.
Each pen contains 10 mg of active substance with purity verified by HPLC.
Composition & specifications
The information below is for reference only and is intended exclusively for research purposes. It is not medical advice.
For research purposes, the literature reports a starting dose of 2 mg once weekly subcutaneously, used to assess tolerance.
Gradual increase to 4 mg weekly. This protocol was used in clinical trials to minimize gastrointestinal side effects.
Clinical research tested doses of 8–12 mg weekly. Always follow the approved research protocol.
Subcutaneous injection into the abdomen, thigh or arm. Rotate the injection site.
Upon receiving the shipment, place the product in a refrigerator immediately (2–8 °C). Do not freeze.
Protect from direct sunlight and heat sources. Keep in the original sealed packaging.
When stored correctly, the product is stable for the period indicated on the packaging. Use according to batch specification after opening.
How long is the pen stable after opening?
Does the pen need to be refrigerated before first use?
What is a CoA (Certificate of Analysis)?
Other products
